Physician profile
Jeffrey D Klausner
NPI 1508973249
$126,288.82
in general payments reported to CMS, 2019-2025
13 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,176 · 2020: $69K · 2021: $6,408 · 2022: $20K · 2023: $17K · 2024: $7,010 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850 · Honoraria: $536 · Food and Beverage: $182 · Travel and Lodging: $94.14 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,234.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850.00 |
| Honoraria | $536.00 |
| Food and Beverage | $181.59 |
| Travel and Lodging | $94.14 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $81,954.79 | 2019-2022 | |
| Glaxosmithkline, LLC. | $13,308.00 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $7,219.19 | 2022 | |
| Roche Diagnostics Corporation | $6,400.00 | 2020-2021 | |
| Abbott Laboratories | $6,000.00 | 2023-2024 | Id Now Instrument |
| Visby Medical, INC. | $5,852.90 | 2022-2025 | Visby Medical Sexual Health Click Test, Visby Medical Respiratory Health Test, Visby Medical Sexual Health Click Test |
| Biofire Diagnostics, LLC | $2,850.00 | 2019-2025 | Biofire Respiratory Panel 2.1, Biofire Respiratory Panel 2.1 |
| Roche Diagnostics International Ltd | $1,497.00 | 2025 | |
| La Jolla Pharmaceutical Company | $701.63 | 2024 | |
| Abbvie INC. | $394.28 | 2022-2025 | |
| Gilead Sciences, INC. | $111.03 | 2024-2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Klausner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.